Tetanus Toxin Cleaves VAMP2 to Boost Photoreceptor Material Transfer

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current approaches to enhance photoreceptor material transfer (MT) in retinal transplantation are limited, with no established methods to effectively promote integration and restoration of visual function in degenerated retinas.

Innovation Solution

Expression of tetanus toxin (TeNT) in donor photoreceptors, which inhibits neurosecretion by cleaving VAMP2, a component of the SNARE complex, thereby enhancing the transfer of intracellular materials to recipient photoreceptors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If photoreceptors are transplanted to restore visual function, then visual function may be restored through material transfer, but the transplanted photoreceptors rarely integrate into the recipient retina and material transfer efficiency is insufficient

Engineering Contradiction:
Improvevisual function restorationVSAvoidmaterial transfer efficiency
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent modifies the molecular parameters of donor photoreceptors by introducing transgenes (RhoA, dominant negative Rac1, or TeNT) that alter cytoskeletal dynamics and neurosecretion. These parameter changes in the donor cells' biochemical state directly enhance material transfer efficiency to recipient photoreceptors, thereby improving visual function restoration without requiring integration of transplanted cells

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent uses photoreceptor nanotubes (PhNTs) as intermediary structures that physically connect donor and host photoreceptors. These nanotube mediators facilitate the transfer of intracellular materials including cytosolic GFP, Cre recombinase, and endogenous phototransduction proteins from donor to recipient cells, enabling indirect rescue of photoreceptor function

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If RhoA or dominant negative Rac1 is expressed in donor cells to regulate PhNT extension and MT, then material transfer is inhibited, but photoreceptor integration may be improved

Engineering Contradiction:
Improvephotoreceptor integrationVSAvoidmaterial transfer
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent inverts the conventional approach by using neurotoxin TeNT to block neurosecretion, which paradoxically enhances material transfer through PhNTs. This inversion of the neurosecretion-blockade concept allows the system to overcome the inhibitory effect of RhoA/Rac1 on material transfer while maintaining photoreceptor integration benefits

Inventive Principle:
Principle #13The other way round (Inversion)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The TeNT expression significantly increases material transfer from transplanted photoreceptors to host cells, providing a novel approach to modulate and enhance MT, potentially restoring visual function in retinal degeneration and damage.

Implementation Method 1

Expression of tetanus toxin (TeNT) in donor photoreceptors, which inhibits neurosecretion by cleaving VAMP2, a component of the SNARE complex

Methodology Applied
Scientific EffectProteolytic cleavage: Enzyme

Implementation Method 2

These observations suggest that cell transplantation-mediated rescue of photoreceptor function is indirect, and at least partially mediated by the transfer of intracellular material to neurons in the recipient retina. MT is facilitated by nanotube-like processes (photoreceptor nanotubes, PhNTs) that connect donor and host photoreceptors in vivo

Methodology Applied
Scientific EffectMaterial transfer through nanotubes: Diffusion

Data Source

PatentUS20230257769A1Transgenic photoreceptors and their use in vision treatment
Publication Date: 2023.08.17 UNIV HEALTH NETWORK
  • US20230257769A1 patent drawing
  • US20230257769A1 patent drawing
  • US20230257769A1 patent drawing

AI summary

There is described herein a photoreceptor cell comprising a neurotoxin transgene, methods for making the same, and use of the same for vision treatment.